While Apogee Therapeutics Inc has overperformed by 3.49%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, APGE fell by -15.60%, with highs and lows ranging from $72.29 to $29.10, whereas the simple moving average fell by -32.11% in the last 200 days.
On November 25, 2024, Canaccord Genuity started tracking Apogee Therapeutics Inc (NASDAQ: APGE) recommending Buy. A report published by BofA Securities on May 10, 2024, Initiated its previous ‘Buy’ rating for APGE. BTIG Research also rated APGE shares as ‘Buy’, setting a target price of $43 on the company’s shares in an initiating report dated December 20, 2023. Wedbush Initiated an Outperform rating on August 08, 2023, and assigned a price target of $40. TD Cowen initiated its ‘Outperform’ rating for APGE, as published in its report on August 08, 2023. Stifel’s report from August 08, 2023 suggests a price prediction of $34 for APGE shares, giving the stock a ‘Buy’ rating. Jefferies also rated the stock as ‘Buy’.
Analysis of Apogee Therapeutics Inc (APGE)
One of the most important indicators of Apogee Therapeutics Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -33.22% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 18.55, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and APGE is recording 545.77K average volume. On a monthly basis, the volatility of the stock is set at 6.83%, whereas on a weekly basis, it is put at 8.08%, with a gain of 1.13% over the past seven days. Furthermore, long-term investors anticipate a median target price of $93.71, showing growth from the present price of $31.43, which can serve as yet another indication of whether APGE is worth investing in or should be passed over.
How Do You Analyze Apogee Therapeutics Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 37.94%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 81.91% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
APGE shares are owned by institutional investors to the tune of 81.91% at present.
